Non-invasive biomarkers of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2013-0-3-97-104
Abstract
Non-invasive biomarkers of chronic obstructive pulmonary disease.
About the Authors
E. Kh. Anaev
ФГБУ "Научно-исследовательский институт пульмонологии" ФМБА России
Russian Federation
Russian Federation
T. N. Anokhina
ФГБУ "Научно-исследовательский институт пульмонологии" ФМБА России
Russian Federation
Russian Federation
M. E. Kushaeva
ФГБУ "Научно-исследовательский институт пульмонологии" ФМБА России
Russian Federation
Russian Federation
A. G. Chuchalin
ФГБУ "Научно-исследовательский институт пульмонологии" ФМБА России
Russian Federation
Russian Federation
References
1. Fischer B.M., Pavlisko E., Voynow J.A. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 413–421.
2. Donaldson G.C., Seemungal T.A., Patel I.S. et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995–2004.
3. Borrill Z.L., Roy K., Singh D. Exhaled breath condensate biomarkers in COPD. Eur. Respir. J. 2008; 32 (2): 472–486.
4. Koczulla A.R., Noeske S., Herr C. et al. Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir. Med. 2012; 106 (1): 120–126.
5. Gerritsen W.B., Asin J., Zanen P. et al. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respir. Med. 2005; 99: 84–90.
6. Leigh R., Pizzichini M.M., Morris M.M. et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27: 964–971.
7. Brightling C.E., McKenna S., Hargadon B. et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193–198.
8. Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867–874.
9. Papaioannou A.I., Mazioti A., Kiropoulos T. et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir. Med. 2010; 104 (2): 275–282.
10. Horvath I., Hunt J., Barnes P.J. et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Respir. J. 2005; 26: 523–548.
11. Popov T.A. Human exhaled breath analysis. Ann. Allergy Asthma Immunol. 2011; 106 (6): 451–456.
12. Taylor D.R. Using biomarkers in the assessment of airways disease. J. Allergy Clin. Immunol. 2011; 128 (5): 927–934.
13. Hoffmeyer F., Raulf,Heimsoth M., Bruning T. Exhaled breath condensate and airway inflammation. Curr. Opin. Allergy Clin. Immunol. 2009; 9 (1): 16–22.
14. Lee W., Thomas P.S. Oxidative stress in COPD and its measurement through exhaled breath condensate. Clin. Transl. Sci. 2009; 2 (2): 150–155.
15. Garey K.W., Neuhauser M.M., Robbins R.A. et al. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest 2004; 125: 22–26.
16. Kostikas K., Papatheodorou G., Psathakis K. et al. Oxidative stress in expired breath condensate of patients with COPD. Chest 2003; 124: 1373–1380.
17. Grob N.M., Aytekin M., Dweik R.A. Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. J. Breath Res. 2008; 2 (3): 037004.
18. Montuschi P., Collins J.V., Ciabattoni G. et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 2000; 162: 1175–1177.
19. Montuschi P., Kharitonov S.A., Ciabattoni G., Barnes P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58: 585–588.
20. Lin J.L., Bonnichsen M.H., Nogeh E.U. et al. Proteomics in detection and monitoring of asthma and smoking-related lung diseases. Expert. Rev. Proteomics 2010; 7 (3): 361–372.
21. Родионов А.А., Ревельский А.И., Ревельский И.А. и др. Хроматомасс-спектрометрическое определение среднелетучих органических веществ в конденсате выдыхаемого воздуха. Масс-спектрометрия 2007; 4 (2): 143–148.
22. Fens N., Zwinderman A.H., van der Schee M.P. et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am. J. Respir. Crit. Care Med. 2009; 180 (11): 1076–1082.
23. Анохина Т.Н. Новые биомаркеры – среднелетучие метаболиты в конденсате выдыхаемого воздуха при бронхиальной астме и хронической обструктивной болезни легких: Автореф. дис. … канд. мед. наук. М.; 2012.
24. de Laurentiis G., Paris D., Melck D. et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur. Respir. J. 2008; 32: 1175–1183.
25. Nicholson J.K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2006; 2: 52.
26. Crameri R. The potential of proteomics and peptidomics for allergy and asthma research. Allergy 2005; 60 (10): 1227–1237.
27. Conrad D.H., Goyette J., Thomas P.S. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J. Gen. Intern. Med. 2008; 23 (Suppl. 1): 78–84.
28. Sepper R., Prikk K. Proteomics: is it an approach to understand the progression of chronic lung disorders? J. Proteome Res. 2004; 3 (2): 277–281.
29. Montuschi P., Kharitonov S.A., Barnes P.J. Exhaled carbon monoxide and nitric oxide in COPD. Chest 2001; 120 (2): 496–501.
30. Liu J., Sandrini A., Thurston M.C. et al. Nitric oxide and exhaled breath nitrite/nitrates in chronic obstructive pulmonary disease patients. Respiration 2007; 74 (6): 617–623.
31. Ferreira I.M., Hazari M.S., Gutierrez C. et al. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effect of inhaled beclomethasone. Am. J. Respir. Crit. Care Med. 2001; 164: 1012–1015.
32. Paredi P., Kharitonov S.A., Leak D. et al. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162 (2, Pt 1): 369–373.
33. Moser B., Bodrogi F., Eibl G. et al. Mass spectrometric profile of exhaled breath – field study by PTR-MS. Respir. Physiol. Neurobiol. 2005; 145: 295–300.
34. Dragonieri S., Schot R., Mertens B.J. et al. An electronic nose in the discrimination of patients with asthma and controls. J. Allergy Clin. Immunol. 2007; 120: 856–862.
35. Borrill Z., Starkey C., Vestbo J., Singh D. Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. Eur. Respir. J. 2005; 25: 269–274.
36. Анаев Э.Х., Чучалин А.Г. Конденсат выдыхаемого воздуха в диагностике и оценке эффективности лечения болезней органов дыхания. Пульмонология 2006; 4: 12–20.
37. Antus B., Barta I., Kullmann T. et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study. Am. J. Respir. Crit. Care Med. 2010; 182 (12): 1492–1497.
38. Kostikas K., Papatheodorou G., Ganas K. et al. pH in expired breath condensate of patients with inflammatory airway diseases. Am. J. Respir. Crit. Care Med. 2002; 165: 1364–1370.
39. Corradi M., Montuschi P., Donnelly L.E. et al. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am. J. Respir. Crit. Care Med. 2001; 163: 854–858.
40. Antczak A., Ciebiada M., Pietras T. et al. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch. Med. Sci. 2012; 8 (2): 277–285.
41. Montuschi P., Macagno F., Parente P. et al. Effects of cyclooxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005; 60: 827–833.
42. Biernacki W.A., Kharitonov S.A., Barnes P.J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294–298.
43. Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
44. Ko F.W., Lau C.Y., Leung T.F. et al. Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respir. Med. 2006; 100: 630–638.
45. Nowak D., Kasielski M., Antczak A. et al. Increased content of thiobarbituric acid reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir. Med. 1999; 93: 389–396.
46. Dekhuijzen P.N., Aben K.K., Dekker I. et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 154: 813–816.
47. van Beurden W.J., Harff G.A., Dekhuijzen P.N. et al. Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration 2003; 70: 242–248.
48. Kasielski M., Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir. Med. 2001; 95: 448–456.
49. Carpagnano G.E., Foschino Barbaro M.P., Cagnazzo M. et al. Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge. Chest 2005; 128: 3159–3166.
50. Carpagnano G.E., Kharitonov S.A., Foschino,Barbaro M.P. et al. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur. Respir. J. 2003; 21: 589–593.
51. Gessner C., Scheibe R., Wotzel M. et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1229–1240.
52. Ko F.W., Leung T.F., Wong G.W. et al. Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 79–86.
53. Bucchioni E., Kharitonov S.A., Allegra L., Barnes P.J. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir. Med. 2003; 97 (12): 1299–1302.
54. Курова В.С., Анаев Э.Х., Кононихин А.С. и др. Массспектрометрический мониторинг белкового состава конденсата выдыхаемого воздуха больного, перенесшего трансплантацию легких. Изв. РАН. Сер. хим. 2010; 1: 284–288.
55. Анаев Э.Х., Кушаева М.Э., Курова В.С. и др. Значение протеомного анализа конденсата выдыхаемого воздуха при диагностике ХОБЛ и пневмонии. Пульмонология 2012; 5: 5–9.
56. Bartoli M.L., Novelli F., Costa F. et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm. 2011: 891752. doi: 10.1155/2011/891752.
57. Schumann C., Triantafilou K., Krueger S. et al. Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm. 2006: 18061.
58. Tateosian N.L., Costa M.J., Guerrieri D. et al. Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients. Cytokine 2012; 58 (3): 361–367.
59. Esther C.R., Lazaar A.L., Bordonali E. et al. Elevated airway purines in COPD. Chest 2011; 140 (4): 954–960.
60. Corradi M., Acampa O., Goldoni M. et al. Metallic elements in exhaled breath condensate and serum of patients with exacerbation of chronic obstructive pulmonary disease. Metallomics. 2009; 1 (4): 339–345.
Review
For citations:
Anaev E.Kh., Anokhina T.N., Kushaeva M.E., Chuchalin A.G. Non-invasive biomarkers of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2013;(3):97-104. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-3-97-104
Views:
890
Email this article 